These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 32328554)

  • 1. Circulating Tumor DNA Analysis: Clinical Implications for Colorectal Cancer Patients. A Systematic Review.
    Bach S; Sluiter NR; Beagan JJ; Mekke JM; Ket JCF; van Grieken NCT; Steenbergen RDM; Ylstra B; Kazemier G; Tuynman JB
    JNCI Cancer Spectr; 2019 Sep; 3(3):pkz042. PubMed ID: 32328554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of ctDNA in colorectal cancer with peritoneal metastases.
    Xue J; Prabhakaran S; Prabhakaran S; Lim WM; Guerra G; Heriot A; Kong JC
    ANZ J Surg; 2023 Mar; 93(3):506-509. PubMed ID: 36200726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.
    Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ
    J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay.
    Lyu N; Rajendran VK; Diefenbach RJ; Charles K; Clarke SJ; Engel A; ; Rizos H; Molloy MP; Wang Y
    Nanotheranostics; 2020; 4(4):224-232. PubMed ID: 32923312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
    van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
    J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
    Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
    PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of KRAS mutations in circulating tumour DNA from plasma and urine of patients with colorectal cancer.
    Ohta R; Yamada T; Sonoda H; Matsuda A; Shinji S; Takahashi G; Iwai T; Takeda K; Ueda K; Kuriyama S; Miyasaka T; Yokoyama Y; Hara K; Yoshida H
    Eur J Surg Oncol; 2021 Dec; 47(12):3151-3156. PubMed ID: 34315643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment.
    Thierry AR; El Messaoudi S; Mollevi C; Raoul JL; Guimbaud R; Pezet D; Artru P; Assenat E; Borg C; Mathonnet M; De La Fouchardière C; Bouché O; Gavoille C; Fiess C; Auzemery B; Meddeb R; Lopez-Crapez E; Sanchez C; Pastor B; Ychou M
    Ann Oncol; 2017 Sep; 28(9):2149-2159. PubMed ID: 28911069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
    Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
    JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].
    Haupts A; Roth W; Hartmann N
    Pathologe; 2019 Dec; 40(Suppl 3):244-251. PubMed ID: 31797045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective capture of plasma cell-free tumor DNA on magnetic beads: a sensitive and versatile tool for liquid biopsy.
    Kerachian MA; Azghandi M; Javadmanesh A; Ghaffarzadegan K; Mozaffari-Jovin S
    Cell Oncol (Dordr); 2020 Oct; 43(5):949-956. PubMed ID: 32495293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Circulating Tumor DNA as a Novel Biomarker to Screen and Diagnose Colorectal Cancer: A Meta-Analysis.
    Min L; Chen J; Yu M; Liu D
    J Clin Med; 2023 Jan; 12(2):. PubMed ID: 36675337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy.
    Boonstra PA; Wind TT; van Kruchten M; Schuuring E; Hospers GAP; van der Wekken AJ; de Groot DJ; Schröder CP; Fehrmann RSN; Reyners AKL
    Cancer Metastasis Rev; 2020 Sep; 39(3):999-1013. PubMed ID: 32367253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Tumor DNA in Patients with Renal Cell Carcinoma. A Systematic Review of the Literature.
    Geertsen L; Koldby KM; Thomassen M; Kruse T; Lund L
    Eur Urol Open Sci; 2022 Mar; 37():27-35. PubMed ID: 35106503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Tumor DNA Detection in the Management of Anti-EGFR Therapy for Advanced Colorectal Cancer.
    Knebel FH; Bettoni F; da Fonseca LG; Camargo AA; Sabbaga J; Jardim DL
    Front Oncol; 2019; 9():170. PubMed ID: 30967998
    [No Abstract]   [Full Text] [Related]  

  • 17. A higher ctDNA fraction decreases survival in regorafenib-treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study.
    Unseld M; Belic J; Pierer K; Zhou Q; Moser T; Bauer R; Piringer G; Gerger A; Siebenhüner A; Speicher M; Heitzer E; Prager GW
    Int J Cancer; 2021 Mar; 148(6):1452-1461. PubMed ID: 32949150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of EGFR Mutations in Circulating Tumor DNA (ctDNA) Retrieved from Plasma - Interlaboratory Quality Assessment in the Czech Republic.
    Linda Č; Markéta K; Ivana T; Eva P; Milada M; Hana V; Ondřej H; Karolína B; Jiří D; Monika B; Pavel D
    Klin Onkol; 2018; 31(5):353-360. PubMed ID: 30541321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS and NRAS mutational analysis in plasma ctDNA from patients with metastatic colorectal cancer by real-time PCR and digital PCR.
    Pinheiro M; Peixoto A; Rocha P; Veiga I; Pinto C; Santos C; Pinto P; Guerra J; Escudeiro C; Barbosa A; Silva J; Teixeira MR
    Int J Colorectal Dis; 2022 Apr; 37(4):895-905. PubMed ID: 35303157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
    Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
    Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.